Reading TOI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TOI free→Reading TOI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TOI free→QuarterlyIQ Insights · TOI
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(-25.0) + peer(0.2*25.0) + term(0.0) → -3.75% (capped ±15.0)
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition On May 7, 2026, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2026 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition On March 12, 2026, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in
Results of Operations and Financial Condition. On January 12, 2026, The Oncology Institute, Inc. (the “Company”) issued a press release reaffirming the Company’s 2025 financial guidance and providing the Company’s preliminary 2026 financial outlook and certain additional longer-term financial guidance. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in this Item 2.02, including Exhibit 99.1, is furnished and…
Results of Operations and Financial Condition On November 13, 2025, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2025 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in
Results of Operations and Financial Condition On August 13, 2025, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended June 30, 2025 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in
Results of Operations and Financial Condition On May 14, 2025, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2025 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in
Results of Operations and Financial Condition On March 24, 2025, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2024 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in